GERMANTOWN, Md. (TheStreet) -- Neuralstem (CUR) is providing an overly optimistic picture about its surgical stem-cell therapy for amyotrophic lateral sclerosis (ALS), the degenerative and fatal nerve disease.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A much-hyped press conference reveals nothing new about Brainstorm's stem-cell therapy for ALS.
Stocks with insider trader activity include TIPT, VER and CUR